Clinical significance of aberrant microRNAs expression in predicting disease relapse/refractoriness to treatment in diffuse large B-cell lymphoma: A meta-analysis.
作者： Choo-Yuen Ting , Su-May Liew , Amy Price , Gin-Gin Gan , Diana Bee-Lan Ong
DOI: 10.1016/J.CRITREVONC.2019.102818
关键词:
摘要: Abstract The clinical significance of aberrantly expressed microRNAs in predicting treatment response to chemotherapy diffuse large B-cell lymphoma patients (DLBCL) remains uncertain. Feasibility microRNA testing predict outcome was evaluated. Twenty-two types were associated with poor response; pooled hazard ratio (HR) 2.14 [95%CI:1.78-2.57, P
sci-hub.se 参考文章(83)
Anas Younes, XIV. The rationale for combining targeted and biological anti-lymphoma drugs. Hematological Oncology. ,vol. 31, pp. 81- 83 ,(2013) , 10.1002/HON.2072
Katharina Troppan, Kerstin Wenzl, Martin Pichler, Beata Pursche, Daniela Schwarzenbacher, Julia Feichtinger, Gerhard Thallinger, Christine Beham-Schmid, Peter Neumeister, Alexander Deutsch, miR-199a and miR-497 Are Associated with Better Overall Survival due to Increased Chemosensitivity in Diffuse Large B-Cell Lymphoma Patients. International Journal of Molecular Sciences. ,vol. 16, pp. 18077- 18095 ,(2015) , 10.3390/IJMS160818077
Huiyun Ni, Xinfeng Wang, Hong Liu, Fuliang Tian, Guoqi Song, Low expression of miRNA-224 predicts poor clinical outcome in diffuse large B-cell lymphoma treated with R-CHOP Biomarkers. ,vol. 20, pp. 253- 257 ,(2015) , 10.3109/1354750X.2015.1068855
Jing Liu, Jinling Xu, Huining Li, Cuiyun Sun, Lin Yu, Yanyan Li, Cuijuan Shi, Xuexia Zhou, Xiuwu Bian, Yifang Ping, Yanjun Wen, Shujun Zhao, Hui Xu, Linlin Ren, Tongling An, Qian Wang, Shizhu Yu, miR-146b-5p functions as a tumor suppressor by targeting TRAF6 and predicts the prognosis of human gliomas Oncotarget. ,vol. 6, pp. 29129- 29142 ,(2015) , 10.18632/ONCOTARGET.4895
Yiting Tang, Xifa Zhou, Jianfeng Ji, Ling Chen, Jianping Cao, Judong Luo, Shuyu Zhang, High expression levels of miR-21 and miR-210 predict unfavorable survival in breast cancer: a systemic review and meta-analysis International Journal of Biological Markers. ,vol. 30, pp. 347- 358 ,(2015) , 10.5301/JBM.5000160
Heounjeong Go, Ji-Young Jang, Pil-Jong Kim, Young-Goo Kim, Soo Jeong Nam, Jin Ho Paik, Tae Min Kim, Dae Seog Heo, Chul-Woo Kim, Yoon Kyung Jeon, MicroRNA-21 plays an oncogenic role by targeting FOXO1 and activating the PI3K/AKT pathway in diffuse large B-cell lymphoma. Oncotarget. ,vol. 6, pp. 15035- 15049 ,(2015) , 10.18632/ONCOTARGET.3729
Inkyung Jung, Ricardo C. T. Aguiar, MicroRNA-155 Expression and Outcome in Diffuse Large B-cell Lymphoma British Journal of Haematology. ,vol. 144, pp. 138- 140 ,(2009) , 10.1111/J.1365-2141.2008.07424.X
R Visconti, R Della Monica, L Palazzo, F D'Alessio, M Raia, S Improta, M R Villa, L Del Vecchio, D Grieco, The Fcp1-Wee1-Cdk1 axis affects spindle assembly checkpoint robustness and sensitivity to antimicrotubule cancer drugs. Cell Death & Differentiation. ,vol. 22, pp. 1551- 1560 ,(2015) , 10.1038/CDD.2015.13
Lin Xia, Dexin Zhang, Rui Du, Yanglin Pan, Lina Zhao, Shiren Sun, Liu Hong, Jie Liu, Daiming Fan, miR-15b and miR-16 modulate multidrug resistance by targeting BCL2 in human gastric cancer cells. International Journal of Cancer. ,vol. 123, pp. 372- 379 ,(2008) , 10.1002/IJC.23501
MATTIAS BERGLUND, GUSTAV HEDSTRÖM, ROSE-MARIE AMINI, GUNILLA ENBLAD, ULF THUNBERG, High expression of microRNA-200c predicts poor clinical outcome in diffuse large B-cell lymphoma. Oncology Reports. ,vol. 29, pp. 720- 724 ,(2013) , 10.3892/OR.2012.2173